Exact Sciences Net Income 2006-2021 | EXAS

Exact Sciences annual/quarterly net income history and growth rate from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Exact Sciences net income for the quarter ending June 30, 2021 was $-0.177B, a 159.81% increase year-over-year.
  • Exact Sciences net income for the twelve months ending June 30, 2021 was $-0.854B, a 416.6% increase year-over-year.
  • Exact Sciences annual net income for 2020 was $-0.849B, a 910.24% increase from 2019.
  • Exact Sciences annual net income for 2019 was $-0.084B, a 52.04% decline from 2018.
  • Exact Sciences annual net income for 2018 was $-0.175B, a 53.11% increase from 2017.
Exact Sciences Annual Net Income
(Millions of US $)
2020 $-849
2019 $-84
2018 $-175
2017 $-114
2016 $-167
2015 $-158
2014 $-100
2013 $-47
2012 $-52
2011 $-29
2010 $-12
2009 $-9
2008 $-10
2007 $-12
2006 $-13
2005 $-15
Exact Sciences Quarterly Net Income
(Millions of US $)
2021-06-30 $-177
2021-03-31 $-31
2020-12-31 $-426
2020-09-30 $-220
2020-06-30 $-68
2020-03-31 $-135
2019-12-31 $78
2019-09-30 $-41
2019-06-30 $-39
2019-03-31 $-83
2018-12-31 $-54
2018-09-30 $-45
2018-06-30 $-36
2018-03-31 $-39
2017-12-31 $-22
2017-09-30 $-27
2017-06-30 $-31
2017-03-31 $-35
2016-12-31 $-37
2016-09-30 $-38
2016-06-30 $-45
2016-03-31 $-47
2015-12-31 $-40
2015-09-30 $-43
2015-06-30 $-39
2015-03-31 $-36
2014-12-31 $-32
2014-09-30 $-32
2014-06-30 $-19
2014-03-31 $-16
2013-12-31 $-12
2013-09-30 $-11
2013-06-30 $-12
2013-03-31 $-11
2012-12-31 $-14
2012-09-30 $-13
2012-06-30 $-15
2012-03-31 $-11
2011-12-31 $-10
2011-09-30 $-8
2011-06-30 $-7
2011-03-31 $-4
2010-12-31 $-4
2010-09-30 $-3
2010-06-30 $-2
2010-03-31 $-2
2009-12-31 $-2
2009-09-30 $-1
2009-06-30 $-2
2009-03-31 $-4
2008-12-31 $-2
2008-09-30 $-3
2008-06-30 $-2
2008-03-31 $-3
2007-12-31 $-4
2007-09-30 $-4
2007-06-30 $-2
2007-03-31 $-2
2006-12-31 $-2
2006-09-30 $-3
2006-06-30 $-3
2006-03-31 $-4
2005-12-31 $-3
2005-09-30 $-3
2005-06-30 $-4
2005-03-31 $-5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $16.808B $1.491B
EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.216B 8.54
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.812B 20.00
Biohaven Pharmaceutical Holding (BHVN) United States $8.815B 0.00
Emergent Biosolutions (EBS) United States $2.763B 6.66
Arcus Biosciences (RCUS) United States $2.321B 0.00
Myovant Sciences (MYOV) United Kingdom $1.993B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.769B 0.00
Zymeworks (ZYME) Canada $1.152B 0.00
Ambrx Biopharma (AMAM) United States $0.431B 0.00
SQZ Biotechnologies (SQZ) United States $0.346B 0.00
Enzo Biochem (ENZ) United States $0.188B 18.43